Palabras clave
Cuestionario de calidad de vida en asma
Asma grave
Dupilumab
Síndrome de hiperventilación
Cómo citar
Resumen
Objective: To assess changes in Nijmegen Questionnaire (NQ) scores in patients with severe asthma treated with dupilumab and their relationship with disease control.
Methods: A retrospective study was conducted in patients with severe asthma treated with dupilumab. Epidemiological and clinical data were collected, as well as results of questionnaires: NQ, asthma control test (ACT) and Asthma Quality of Life Questionnaire (AQLQ), assessing the changes after one year of treatment.
Results: A total of 18 patients were included, 12 males, with a median age of 54 years and a range between 27 and 67 years old. The median result of the NQ at the start of dupilumab was 15.5 points (1-34) and at 12 months was 7 points (0-35). Before treatment, five patients (27.77%) had a NQ greater than 23 points compatible with hyperventilation syndrome (HVS). The median ACT score was 19 (10-24) and at the 12-month control it was 23 (12-25). The median AQLQ was 5 points (3-7) at the start of dupilumab and 6.08 points (3.50-7) after 12 months of dupilumab. This study observed changes in NQ scores after 12 months of dupilumab treatment, irrespective of initial NQ scores.
Conclusions: Incorporating the NQ into the assessment of biologic response in severe asthma may provide additional insights into patient monitoring. Proper management of comorbidities, including HVS, is essential for optimizing asthma outcomes, as uncontrolled comorbidities can confound asthma control.
Keywords: Nijmegen questionnaire; Asthma quality of life questionnaire; Severe asthma; Dupilumab; Hyperventilation syndrome.
Referencias
1. Howell JB. The hyperventilation syndrome: a syndrome under threat?. Thorax 1997; 52 (Suppl 3): S30-S34. doi: 10.1136/thx.52.2008.s30
2. Morgan MD. Dysfunctional breathing in asthma: is it common, identifiable and correctable?. Thorax 2002; 57 (Suppl 2): II31-II35.
3. Boulding R, Stacey R, Niven R, Fowler SJ. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev 2016; 25 (141): 287-294. doi: 10.1183/16000617.0088-2015
4. Van Dixhoorn J, Duivenvoorden HJ. Efficacy of Nijmegen Questionnaire in recognition of the hyperventilation syndrome. J Psychosom Res 1985; 29 (2): 199-206. doi: 10.1016/0022-3999(85)90042-x
5. Thomas M, McKinley RK, Freeman E, Foy C, Price D. The prevalence of dysfunctional breathing in adults in the community with and without asthma. Prim Care Respir J 2005; 14 (2): 78-82. doi: 10.1016/j.pcrj.2004.10.007
6. Grammatopoulou EP, Skordilis EK, Georgoudis G, et al. Hyperventilation in asthma: a validation study of the Nijmegen Questionnaire--NQ. J Asthma 2014; 51 (8): 839-846. doi: 10.3109/02770903.2014.922190
7. Thomas M, Bruton A, Ainsworth B. Use of the Nijmegen Questionnaire in asthma. ERJ Open Res 2015; 1 (1): 00033-2015. doi: 10.1183/23120541.00033-2015
8. Hekking PP, Amelink M, Wener RR, Bouvy ML, et al. Comorbidities in Difficult-to-Control Asthma. J Allergy Clin Immunol Pract 2018; 6 (1): 108-113. doi: 10.1016/j.jaip.2017.06.008
9. Hagman C, Janson C, Emtner M. Breathing retraining - a five-year follow-up of patients with dysfunctional breathing. Respir Med 2011; 105 (8): 1153-1159. doi: 10.1016/j.rmed.2011.03.006
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2025 Revista Alergia México